The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and ...

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...

May 4 () - Amgen said on Monday it was investing an additional $300 ‌million in Puerto Rico to expand ‌its U. Global ...

Dr. Howard Chang, fourth from left, Amgen's senior vice president global research & chief scientific officer, with fellows in the biotech company's new postbaccalaureate fellowship program. The ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...